We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
SKYE

Price
2.16
Stock movement up
+0.05 (1.43%)
Company name
Skye Bioscience, Inc. Common Stock
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
110.01M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-27.25%
3 year return
-19.28%
5 year return
-22.26%
10 year return
-35.78%
Last updated: 2025-09-15

iO Charts is a Seeking Alpha partner

DIVIDENDS

SKYE does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

FINANCIALS

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open3.51
Daily high3.75
Daily low3.36
Daily Volume300K
All-time high1937.50
1y analyst estimate14.29
Beta2.21
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
SKYES&P500
Current price drop from All-time high-99.82%-1.46%
Highest price drop-99.94%-56.47%
Date of highest drop8 Apr 20259 Mar 2009
Avg drop from high-94.52%-10.99%
Avg time to new high536 days12 days
Max time to new high2673 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
SKYE (Skye Bioscience, Inc. Common Stock) company logo
Marketcap
110.01M
Marketcap category
Small-cap
Description
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Employees
16
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...